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A B S T R A C T
In order to survive, Aspergillus fumigatus must adapt to speciﬁc niche environments. Adaptation to the human
host includes modiﬁcations facilitating persistent colonisation and the development of azole resistance. The aim
of this study is to advance understanding of the genetic and physiological adaptation of A. fumigatus in patients
during infection and treatment. Thirteen A. fumigatus strains were isolated from a single chronic granulomatous
disease patient suﬀering from persistent and recurrent invasive aspergillosis over a period of 2 years. All strains
had identical microsatellite genotypes and were considered isogenic. Whole genome comparisons identiﬁed 248
non-synonymous single nucleotide polymorphisms. These non-synonymous mutations have potential to play a
role in in-host adaptation. The ﬁrst 2 strains isolated were azole susceptible, whereas later isolates were itra-
conazole, voriconazole and/or posaconazole resistant. Growth assays in the presence and absence of various
antifungal stressors highlighted minor changes in growth rate and stress resistance, with exception of one isolate
showing a signiﬁcant growth defect. Poor conidiation was observed in later isolates. In certain drug resistant
isolates conidiation was restored in the presence of itraconazole. Diﬀerences in virulence were observed as
demonstrated in a Galleria mellonella infection model.We conclude that the microevolution of A. fumigatus in this
patient has driven the emergence of both Cyp51A-independent and Cyp51A-dependent, azole resistance me-
chanisms, and additional phenotypes that are likely to have promoted fungal persistence.
1. Introduction
Aspergillus fumigatus is a ubiquitous saprophytic fungus. Its ecolo-
gical niche is soil, where it plays a key role in carbon and nitrogen
recycling by degradation of organic biomass (O’Brien et al., 2005;
Tedersoo et al., 2014). Various characteristics enable A. fumigatus to
survive in this harsh environment, including rapid germination, growth
at higher temperatures and nutritional metabolic ﬂexibility (Mullins
et al., 1976). This versatility enables A. fumigatus to be a successful
pathogen in human, animal and plant populations (Armstrong-James
et al., 2016; Fisher et al., 2012).
In humans, A. fumigatus is the causative agent of aspergillosis, which
ranges from allergic syndromes to life-threatening invasive aspergillosis
(Latgé, 2001; Warris, 2014). Azole antifungal agents hold great im-
portance in the treatment of aspergillosis, as they are the only orally
available anti-Aspergillus agents (Patterson et al., 2016; Peyton et al.,
2015; Warris, 2014). The primary target of azoles is cytochrome P450
14α-sterol demethylase (Cyp51A), which catalyses the demethylation
of ergosterol precursors in the ergosterol biosynthetic pathway
(Bosschef et al., 1995; Ghannoum and Rice, 1999; Shapiro et al., 2011).
Azoles competitively inhibit Cyp51A by binding to the haem active site
(Gollapudy et al., 2004; Xiao et al., 2004).
In order to survive and thrive in-host, A. fumigatus must adapt to
speciﬁc niche environments (Verweij et al., 2016). Genetic adaptation
can be deﬁned as the acquisition of heritable modiﬁcations, via either
spontaneous mutation or recombination, which enable survival and
reproduction in the environment (Schoustra et al., 2005). Examples of
adaptation include adaptation to enable persistent infection and azole
resistance development (Fedorova et al., 2008; Hagiwara et al., 2014;
Kano et al., 2015; Valsecchi et al., 2015; Verweij et al., 2016). The in-
host acquisition of resistance has previously been described within as-
pergillomas in chronic pulmonary aspergillosis (Howard et al., 2013).
Since the ﬁrst report of itraconazole resistance in A. fumigatus in
1997 (Denning et al., 1997), azole resistance is increasingly reported
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globally. A range of molecular mechanisms conferring azole resistance
have been described. Speciﬁc non-synonymous point mutations in
cyp51A have been shown to confer azole resistance by altering the li-
gand entry channel structure; examples include G54, P216, G138 and
M220 (Albarrag et al., 2011; Garcia-Eﬀron et al., 2005; Mann et al.,
2003; Mellado et al., 2004, 2003; Snelders et al., 2010). A tandem re-
peat of 34 bp in the promoter region of cyp51A has also been shown to
confer itraconazole resistance by increasing cyp51A gene expression in
combination with an L98H mutation within cyp51A (Mellado et al.,
2007; Snelders et al., 2008). In contrast to cyp51A-mediated resistance
mechanisms, relatively few non cyp51A-mediated mechanisms have
been described. One example is a P88L substitution in the CCAAT-
binding transcription factor complex subunit HapE, which has been
shown to confer itraconazole resistance by enhancing cyp51A expres-
sion (Camps et al. 2012). Overexpression of eﬄux transporters AtrF and
Cdr1B has been associated with azole resistance (Fraczek et al., 2013;
Slaven et al., 2002) but further research is required to validate the role
of these pumps in azole resistance. Mutation in components of mi-
tochondrial complex I, RamA (farnesyltransferase β-subunit), over-
expression of cyp51B and deletion of cytochrome b5 CybE have also
been described to result in azole resistance (Bromley et al., 2016; Buied
et al., 2013; Misslinger et al., 2017; Norton et al., 2017).
Cyp51A-mediated resistance mechanisms are not thought to be as-
sociated with ﬁtness costs (Lackner et al., 2017; Valsecchi et al., 2015).
In contrast, the HapE itraconazole resistance mechanism is associated
with a growth defect (Camps et al. 2012). Interestingly, speciﬁc azole
resistant isolates are hypothesised to be ‘azole addicted’ whereby they
exhibit enhanced growth in the presence of azole antifungals
(Anderson, 2005; Schoustra et al., 2006).
Studies investigating the dynamics of in-host adaptation and per-
sistent infection are scarce. Here we performed a detailed phenotypic
and genotypic analysis of 13 A. fumigatus isolates consecutively cul-
tured over a period of 2 years with increasing azole resistance in a
chronic granulomatous disease (CGD) patient with chronic and re-
current aspergillosis. Whole genome sequencing was used to assess the
genomic dynamics. Phenotypic analysis including growth in liquid and
on solid media and conidiation assays were used to investigate phy-
siological adaptation. An invertebrate infection model was used to as-
sess diﬀerences in virulence.
2. Materials and methods
2.1. Origin and characterisation of fungal isolates
The 13 isolates used in this study were cultured from a 36-year-old
male diagnosed with X-linked chronic granulomatous disease with se-
vere chronic obstructive pulmonary disease (Gold IV) and allergic
bronchopulmonary aspergillosis (Verweij et al., 2016). The patient
suﬀered from 3 episodes of invasive aspergillosis and developed an
aspergilloma, which could not be surgically removed due to his poor
respiratory condition. The patient was treated prophylactically with
interferon-gamma, trimethoprim-sulphamethoxazole and itraconazole.
Between June and December 2011, the patient was treated with itra-
conazole followed by combination therapy consisting of voriconazole
and an echinocandin (caspofungin, anidulafungin). Isolate V130-15 was
collected on 22/11/11 and isolates V130-14, V130-18 and V130-54
were collected on 25/11/11. Between December 2011 and January
2013 the patient was treated consecutively with liposomal amphoter-
icin B, itraconazole, anidulafungin in combination with voriconazole.
Between August and December 2013, the patient was treated with
posaconazole monotherapy, followed by combination therapy with
micafungin. Despite these eﬀorts, eradication of the fungus was not
achieved. Isolates V157-39, V157-40, V157-47, V157-48 and V157-62
were collected on 9/12/13. Isolates V157-59, V157-60 and V157-61
were collected on 12/12/13; and isolate V157-80 was collected on 19/
12/13. Unfortunately the patient died from his infection.
The 13 A. fumigatus isolates were cultured and morphologically
identiﬁed as A. fumigatus at Radboud University Medical Centre
(Verweij et al., 2016). In vitro susceptibility testing of the isolates was
performed according to the EUCAST broth microdilution reference
method (Subcommittee on Antifungal Susceptibility Testing of the
ESCMID European Committee for Antimicrobial Susceptibility Testing
(EUCAST), 2015). Isolates were tested at a ﬁnal drug concentration rage
of 0.0312–16mg/L itraconazole (Sigma Aldrich, UK), 0.0312–16mg/L
voriconazole (Pﬁzer, UK) and 0.0156–8mg/L posaconazole (Sigma
Aldrich, UK). A no growth end point was determined by eye. Short
tandem repeat (STR) typing was performed as described previously
using microsatellite loci STRAf 3A, 3B, 3C, 4A, 4B and 4C (de Valk
et al., 2005). Repeat numbers at each loci were determined by PCR and
subsequent sequencing.
2.2. Conidial suspension preparation
A. fumigatus conidia were spread onto diluted Sabouraud dextrose
agar in T75 culture ﬂasks (Greiner Bio-One, Germany) and incubated at
37 °C for 7 d. Diluted Sabouraud dextrose agar was selected to promote
sporulation. Conidia were harvested via immersion in 30mL phosphate
buﬀered saline (PBS) (Thermo Fisher Scientiﬁc, UK) containing 0.05%
Tween-80 (Thermo Fisher Scientiﬁc, UK). Conidial suspensions were
passed through a sterile 40 µm strainer to remove hyphal fragments,
washed twice using PBS and then counted using a Neubauer improved
haemocytometer (Petrikkou et al., 2001). For all experiments, suspen-
sions were diluted as required in RPMI (RPMI 1640+Glutamax, Fisher
Scientiﬁc, UK).
2.3. Whole genome sequencing
DNA was extracted from either conidia or mycelium. Conidia were
suspended in TE buﬀer (pH 8, 1% SDS, 2% Triton X100, 100mM NaCl).
The suspension was shaken for 30min at 70 °C. DNA was extracted
using phenol/chloroform extraction and puriﬁed using the QIAamp
DNA Blood Mini kit (Qiagen, Germany). A fragmented genomic DNA
library was prepared using a Nextera XT DNA sample preparation kit
(Illumina, USA). Subsequent sequencing was conducted in a paired end
2×150 bp mode using an Illumina NextSeq 500 machine (Illumina,
USA).
2.4. Bioinformatics analysis
Raw reads were quality checked using FastQC (version 0.11.5,
Babraham Institute). Reads containing adapter sequences and/or with a
Phred score< 30 were removed using Trimmomatic (Galaxy version
0.32.3) (Bolger et al., 2014; Giardine et al., 2005). Reads were mapped
to the Af293 reference genome (release 31, EnsemblFungi) using the
very sensitive local align preset mode in Bowtie2 (Garcia-Alcalde et al.,
2012). Mapping quality was assessed using Qualimap (Garcia-Alcalde
et al., 2012; Okonechnikov et al., 2015). Single nucleotide poly-
morphism (SNP) detection was conducted using FreeBayes (Garrison
and Marth, 2012). VCFtools vcf-isec was used to assess patterns
amongst SNPs and to ﬁlter SNPs with a minimum coverage of 5 and a
minimum probability of 0.8 (Danecek et al., 2011). EnsemblFungi
Variant Eﬀect Predictor was used to assess the impact of non-synon-
ymous SNPs (Flicek et al., 2014). Both synonymous and non-synon-
ymous SNPs were considered for phylogenetic analysis using the
SNPhylo pipeline (Lee et al., 2014), which utilises vcftools (Danecek
et al., 2011), Phylip (University of Washington, USA) and Muscle
(Edgar, 2004) to generate phylogenetic trees by the maximum like-
lihood method. Integrated Genomics Viewer and Tablet were utilised
for visualisation of sequence data (Boyaval et al., 2007; Milne et al.,
2013; Thorvaldsdóttir et al., 2013).
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2.5. Growth assays
2.5.1. Liquid medium
Flat-bottomed 96-well plates (Nunc microwell 96F, Thermo Fischer
Scientiﬁc, UK) were seeded with 1.9×105 conidia in RPMI. Selected
wells were supplemented with speciﬁc concentrations of posaconazole
(POS 0.5–1mg/L), voriconazole (VORI 1–4mg/L) or 2.5mM tert-Butyl
hydroperoxide (tBOOH) (Sigma Aldrich, UK). Plates were incubated at
37 °C for 48 h inside a spectrophotometric plate reader (FLUOstar
OPTIMA, BMG Labtech, Germany). Optical density at 450 nm was au-
tomatically measured every 20min with 5 s shaking before every
reading. Each condition was performed in triplicate wells and repeated
twice. Due to the lipophilic properties of itraconazole (ITR), speciﬁc
concentrations were unable to be determined in liquid media; solid
media assays were consequently used for studying the impact of ITR on
growth.
2.5.2. Solid medium
Sabouraud dextrose agar plates were spot-inoculated with 5×102
conidia. Selected plates were supplemented with speciﬁc concentra-
tions of either ITR (between 1 and 8mg/L) or 2.5 mM tBOOH.
Supplements were added to the medium at∼50 °C before solidiﬁcation.
Plates were incubated at 37 °C for 96 h, colony diameters were mea-
sured every 24 h. Each condition was performed in triplicate.
2.5.3. Environmental zinc depletion
A. fumigatus conidia were spread onto glucose minimal agar lacking
zinc in T75 culture ﬂasks and incubated at 37 °C for 7 d. Conidia were
harvested and counted as described. Zinc depletion experiments were
performed by spot inoculating 5× 102 conidia on glucose minimal
media in the absence and presence of 1mM zinc at pH 4.5 and 7.5
(Amich et al., 2010). Plates were incubated at 37 °C for 96 h, colony
diameters were measured every 24 h. Each condition was performed in
triplicate.
2.5.4. Conidiation quantiﬁcation
T75 culture ﬂasks containing Sabouraud dextrose agar were in-
oculated with 1×105 conidia and incubated at 37 °C for 7 d. Selected
ﬂasks were supplemented with 4mg/L ITR. Conidial suspensions were
prepared and counted as described above. Where sterile hyphae were
produced, a 1 cm3 section of hyphae was excised using a sterile plastic
loop, re-plated and incubated at 37 °C for an additional 7 d. Conidial
suspensions were subsequently prepared and counted as described.
Each condition was performed in duplicate.
2.6. Galleria mellonella virulence assays
Similar sized G. mellonella larvae (Livefood Ltd, UK) were selected
for use in experiments. All larval injections were performed in the last
pro-leg using a 0.33mm Micro-Fine needle (BD, UK). Groups of 10
larvae were infected with 6×103 conidia. Control groups of larvae
were included in each experiment; 10 unmanipulated larvae and 10
larvae injected with 10 µl PBS. Larvae were incubated at 37 °C for 6 d.
Larval death was characterised by lack of movement and melanisation
(Gomez-Lopez et al., 2014; Renwick et al., 2006; Slater et al., 2011).
Virulence assays were performed in duplicate.
2.7. Statistical analysis
Statistical signiﬁcance was assessed using a two-tailed Students T-
test. Survival curves comparisons were performed using a log-rank
Mantel-Cox test. A p value of< 0.05 was considered signiﬁcant.
3. Results
3.1. Initial characterisation of the A. Fumigatus isolates
3.1.1. Validation of genetic relatedness
Microsatellite typing was performed in order to verify genetic re-
latedness between the 13 isolates (de Valk et al., 2005). STRAf loci 3A,
3B, 3C, 4A, 4B and 4C were assessed. All isolates showed identical re-
peat numbers at all loci except for 3C and 4A. Isolates showed 26 re-
peats at 3A, 9 repeats at 3B, 12 repeats at 4B and 8 repeats at 4C. At
locus 3C isolates showed 16 repeats, with the exception of isolates
V130-15 and V130-18 which showed 17 repeats. At locus 4A isolates
showed 9 repeats, with the exception of isolates V157-39, V157-40 and
V157-80 which showed 8 repeats. As repeat numbers at these loci dif-
fered by only one single repeat the isolates are considered isogenic.
3.1.2. Development of triazole resistance
According to the EUCAST clinical resistance breakpoints, isolates
V130-15 and V130-14 were azole susceptible, while isolate V130-54
was itraconazole (ITR) resistant. Furthermore, isolates V130-18, V157-
62, V157-59, V157-60 and V157-61 were pan-azole resistant, whereas
isolates V157-39, V157-40, V157-47, V157-48 and V157-80 were ITR
and posaconazole (POS) resistant (Table 1).
3.1.3. Diﬀerences in colony morphology
Colony morphology diﬀered hugely between isolates. The ﬁrst 5
Table 1
Minimum inhibitory concentrations of the A. fumigatus isolates in the series.
Isolation date Strain Cyp51A SNP Minimum inhibitory concentration (MIC; mg/L)
Itraconazole Voriconazole Posaconazole
22/11/11 V130-15 1 1 0.25
25/11/11 V130-14 1 1 0.25
25/11/11 V130-18 4 4 0.5
25/11/11 V130-54 >16 1 0.125
09/12/13 V157-39 G54R >16 1 >16
09/12/13 V157-40 G54V >16 1 >16
09/12/13 V157-47 P216L >16 2 >16
09/12/13 V157-48 P216L >16 2 >16
09/12/13 V157-62 M220R >16 8 >16
12/12/13 V157-59 M220R >16 4 >16
12/12/13 V157-60 M220R >16 4 >16
12/12/13 V157-61 M220R >16 4 >16
19/12/13 V157-80 P216L >16 1 >16
Bold indicates a MIC exceeding the EUCAST clinical resistance breakpoint; which are deﬁned as itraconazole> 2mg/L, voriconazole> 2mg/L and posaconazole>0.25mg/L.
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isolates (V130-15, V130-14, V130-18, V130-54, V157-39 and V157-40)
produced wild-type green colonies whereas subsequent isolates pro-
duced predominantly white, sterile hyphae. Remarkably, the ﬁnal iso-
late collected (V157-80) produced green1 colonies again (Fig. 1).
3.2. In depth characterisation of the isolates
3.2.1. Whole genome comparisons between isolates
Af293 was used as the reference genome based on assessment of
mapping quality and coverage statistics; mean coverage across the
series was 65X and mean mapping quality was 40 (Table A.1). SNP-
based full genome phylogenetic analysis was performed (Lee et al.,
2014). The sequences of various unrelated isolates were included in the
phylogenetic analysis; a clinical isolate from Japan (IFM59361-1)
Fig. 1. Observed colony morphology of the series. Sabouraud dextrose agar plates were spot inoculated with 5× 102 conidia and incubated at 37 °C for 96 h.
Fig. 2. Phylogenetic tree based on whole genome sequences of the A. fumigatus series. (A) Single nucleotide polymorphism based phylogenetic tree was constructed using the SNPhylo
pipeline and the whole genome sequences of the entire series as well as unrelated isolates IFM59361-1, 09-7500806, 08-19-02-61 and Afu 1042/09. (B) Unrooted phylogenetic tree of the
series constructed using the SNPhylo pipeline. Tree scale represents nucleotide substitutions per site.
1 For interpretation of color in Fig. 1, the reader is referred to the web version of this
article.
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(Hagiwara et al., 2014), a clinical isolate from the UK (09-7500806)
(Abdolrasouli et al., 2015), an environmental isolate from the Nether-
lands (08-19-02-61) (Abdolrasouli et al., 2015) and a clinical isolate
from India (Afu 1042/09) (Abdolrasouli et al., 2015). Fig. 2A highlights
the genetic closeness of the series, as unrelated isolates showed greater
genetic distance and diversity. In agreement with microsatellite typing
results, whole genome sequencing veriﬁed the isolates to be isogenic
(Fig. 2A). The ﬁrst strain to be isolated (V130-15) was veriﬁed to be the
precursor to the series (Fig. 2B). Later isolates appear to take on in-
dependent lineages of microevolution from the precursor isolate.
A total of 248 non-synonymous SNPs, absent in early isolates V130-15
and V130-14, were identiﬁed in later isolates (Table A.2). These SNPs are
predicted to have developed during the course of infection and in-host
microevolution of the precursor strain (V130-15). SNPs of particular in-
terest were identiﬁed based on their occurrence in multiple isolates or
being localised in genes encoding proteins considered to play an important
role in fungal cell metabolism and growth (Table 2). The genes identiﬁed
were located across all 8 chromosomes and encoded a range of proteins
including phospholipases (AFUA_3G07940 phosphoinositide phospholi-
pase C), protein kinases (AFUA_2G01700 Snf1) and cell division control
proteins (AFUA_3G10250 Cdc15). Cyp51A SNPs were identiﬁed in 9 iso-
lates in the series. V157-39 harboured G54R; V157-40 harboured G54V;
isolates V157-47, V157-48 and V157-80 harboured P216L; isolates V157-
59, V157-60, V157-62 and V157-61 harboured M220R. SNPs were also
identiﬁed in a range of uncharacterised proteins. For example, V204A SNP
in AFUA_4G08100 was demonstrated in isolates V157-39, V157-48, V157-
59, V157-60, V157-62, V157-61 and V157-80. A wide range of Cyp51A
SNPs were identiﬁed, supporting the prediction that the isolates took on
independent lineages of microevolution (Fig. 2B).
Of the SNPs identiﬁed, of particular interest was F125L in ZrfC al-
kaline zinc transporter (AFUA_4G09560) in the last isolate of the series,
V157-80. F125L lies in the highly conserved ETFCND motif, which is C-
terminal of a zinc-binding motif (Macpherson et al., 2005). The strict
conservation of this motif indicates importance (Macpherson et al.,
2005). Zinc depletion assays were performed in order to assess whether
this isolate possessed any growth diﬀerences as a result of this SNP in
zinc-limiting environments, much like the human host.
Isolate V157-40 was selected as a control strain with a similar ge-
netic background; both V157-40 and V157-80 possessed
MICs > 16mg/L for both ITR and POS. There were no signiﬁcant
growth diﬀerences between isolates V157-40 and V157-80 in the pre-
sence and absence of 1mM zinc at pH 4.5 and 7.5. Both isolates ex-
hibited signiﬁcantly enhanced colony growth in the absence of zinc at
pH 7.5 in comparison to pH 4.5 (p < 0.05). In the presence of zinc,
growth diﬀerences between pH 4.5 and 7.5 were negligible in bothTa
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Fig. 3. Comparison of mycelial growth of A. fumigatus isolates V157-40 and V157-80 in
the presence and absence of zinc at pH 4.5 and 7.5. Isolates were pre-cultured on glucose
minimal media lacking zinc for 7 d at 37 °C. Conidia were harvested via immersion in
30mL PBS containing 0.05% Tween-80 and counted. Glucose minimal media plates
lacking zinc or containing 1mM zinc at pH 4.5 and 7.5 were spot inoculated with 5×102
conidia. Every 24 h for 96 h colony diameter was measured; results at 96 h are shown.
Data was obtained in triplicate and mean values ± SD are shown (*p < 0.05; two-tailed
Students T-test).
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isolates (Fig. 3). In summary, the SNP observed in ZrfC does not appear
aﬀect the ability to scavenge zinc under the conditions tested.
3.2.2. Phenotypic analysis
The isolates showed variations in their growth kinetics in control
liquid and solid media. The mean OD450 after 48 h growth in liquid
media ranged from 0.666 (V130-18) to 0.818 (V157-48) (p=NS). All
isolates cultured on solid media for 96 h showed growth colony dia-
meters of between 30.2 (V130-14) and 37.5 mm (V157-39) (p=NS).
Isolate V157-62 was an exception to this range. This isolate possessed a
signiﬁcantly decreased mean 96 h colony diameter of 16.2 mm
(p=0.003 compared to the mean of isolates V130-15, V157-39, V157-
47 and V157-59). This represents a mycelial growth rate 52% slower
than the other isolates (Figs. 1 and 4). Speciﬁc isolates (V130-15, V157-
39, V157-47, V157-62 and V157-59) were selected for detailed phe-
notypic analyses to assess their response to antifungal stressors. These
isolates were considered representative of the diﬀerent azole resistance
proﬁles, Cyp51A mutations and growth rates observed in the series. As
shown in Table 1, V130-15 was azole susceptible without Cyp51A SNPs;
V157-39 harboured G54R in Cyp51A and was ITR and POS resistant;
V157-47 harboured P216L in Cyp51A and was ITR and POS resistant;
V157-62 had a growth defect, harboured M220R in Cyp51A and was
ITR, VORI and POS resistant; V157-59 harboured M220R in Cyp51A
and was ITR, VORI and POS resistant. As anticipated, in both solid and
liquid media, isolates were unable to grow in the presence of a mould-
active azole at a concentration higher than its MIC. Resistant isolates
exhibited a concentration dependent decrease in growth in the presence
of azole antifungal agents in both solid and liquid media (Figs. 4 and 5).
None of the isolates exhibited enhanced growth in comparison to
control conditions in the presence of azole antifungals.
The series of strains were isolated from a CGD patient. This group of
patients possess a defect in the nicotinamide adenine dinucleotide
phosphate (NAPDH) oxidase complex, this results in a failure to mount
a phagocyte respiratory burst and produce superoxide (King et al.,
2016). In order to assess whether the isolates displayed enhanced
sensitivity to oxidative stress, as a result of adaptation in the CGD host,
growth in the presence of tBOOH was assessed in both liquid and on
solid media. Growth of all 5 isolates was fully inhibited by the presence
of 2.5 mM tBOOH (data not shown). All 5 isolates grew normally at
lower concentrations, indicating normal sensitivity to oxidative stress
(Emri et al., 2015).
In order to further investigate the growth and development of the
isolates, conidiation levels were quantiﬁed (Fig. 6). Under control
conditions, speciﬁc resistant isolates (V157-39, V157-40, V157-47,
V157-48, V157-62, V157-59, V157-60, V157-61, and V157-80) pro-
duced on average 5-fold less conidia than earlier isolates (V130-15,
Fig. 5. Growth kinetics of selected A. fumigatus isolates in liquid media. Flat-bottomed 96-well plates were seeded with 1×105 conidia in RPMI with or without voriconazole (A) or
posaconazole (B) in various concentrations. Plates were incubated at 37 °C for 48 h inside a spectrophotometric plate reader; the optical density at 450 nm was automatically measured
every 20min with 5 s shaking before every reading. Optical density at 48 h is shown. Data was obtained in duplicate, mean values ± SD are shown. No signiﬁcant diﬀerences were
observed between isolates under the same condition.
Fig. 4. Comparison of mycelial growth of selected A. fumigatus isolates on solid media
with increasing concentrations of itraconazole. Sabouraud dextrose agar plates were spot
inoculated with 5×102 conidia and incubated at 37 °C. Colony diameter was measured
every 24 h for 96 h; results for 96 h are shown. Data was obtained in triplicate and mean
values ± SD are shown (*p=0.003 compared to mean of V130-15, V157-39, V157-47
and V157-59; two-tailed Students T-test).
Fig. 6. Comparison of amount of conidia produced by the A. fumigatus strains throughout
the series. T75 culture ﬂasks containing Sabouraud dextrose agar with or without the
addition of 4mg/L itraconazole, were inoculated with 1x105 conidia and incubated at
37 °C for 7 d. Conidial suspensions were prepared via immersion in 30mL PBS containing
0.05% Tween-80 and counted. Data was obtained in duplicate and mean values ± SD are
shown (*p=0.023, **p= 0.0009; two-tailed Students T-test).
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V130-14, V157-18 and V157-54) (p= 0.038). Conidia production in
ITR resistant isolates (V157-39, V157-40, V157-47, V157-62, V157-60
and V157-80) increased on average 7-fold in the presence of 4mg/L ITR
(p=0.041). Isolates V157-39 and V157-62 produced 5-fold
(p=0.023) and 3-fold (p= 0.0009) more conidia respectively in the
presence of 4mg/L ITR than susceptible isolates under control condi-
tions. In summary, the majority of resistant isolates displayed increased
levels of conidiation in the presence of 4mg/L ITR. Isolates V157-48,
V157-59 and V157-61 did not display this trend. However, upon pas-
saging sterile hyphae onto 4mg/L ITR, enhanced sporulation was ob-
served.
3.2.3. Diﬀerences in virulence between isolates
In order to assess associated changes in virulence in the series,
survival studies were performed using the well-established invertebrate
model of systemic infection, Galleria mellonella (Gomez-Lopez et al.,
2014; Renwick et al., 2006; Slater et al., 2011). Clear diﬀerences in
mortality rates were observed for the isolates tested (Fig. 7). The per-
centage survival at 6 d ranged from 10% (isolate V157-39) to 60%
(isolate V157-62). The percentage survival at 6 d was 40% after infec-
tion with the ﬁrst isolate (V130-15). Survival after infection with isolate
V157-62, the only isolate with a growth defect, was signiﬁcantly higher
than after infection with isolate V130-15 (p= 0.037). Survival after
infection with isolate V157-39 was signiﬁcantly lower than after in-
fection with isolate V130-15 (p=0.01). No associations between
virulence and conditions levels and/or resistance proﬁle could be made.
4. Discussion
In this study we investigated the dynamics of both physiological and
genetic adaptation in A. fumigatus throughout chronic and recurrent
infection. Central to this study was our series of 13 isolates obtained
from a single chronic granulomatous disease patient over a period of
2 years. Using this unique series, we identiﬁed large numbers of genetic
changes thought to have occurred throughout infection and disease.
These non-synonymous mutations identiﬁed have potential to play a
role in adaptation to the human host under antifungal therapy.
Additionally, we identiﬁed one isolate that displays a severe growth
defect. We also observed signiﬁcant diﬀerences in the ability of the
isolates to produce conidia. Isolates were demonstrated to exhibit
varying levels of virulence and be more equipped to cope with zinc
depletion at pH 7.5 in comparison to pH 4.5, which is consistent with
previous ﬁndings (Amich et al., 2010).
It is hypothesised that advantageous SNPs, which have developed
during natural random mutation, are selected for during exposure to in-
host stressors, such as azoles and eﬀectors of the innate immunity.
Subsequent natural selection is thought to enable survival. Here, we
identiﬁed 248 SNPs predicted to have arisen during the course of in-
fection in one host. Speciﬁc proteins were mutated in multiple isolates
in the series. The identiﬁed proteins are involved in a wide range of
cellular activities, indicating the stressors present in-host to be equally
wide ranging. It is expected that the identiﬁed proteins play a role in in-
host adaptation. Azole target Cyp51A is a hotspot for mutations con-
ferring azole resistance (Zoll et al., 2016). Nine isolates within our
series contained a SNP in Cyp51A. As the initial susceptible isolates
lacked Cyp51A SNPs it can be concluded that these SNPs developed in-
host, presumably as a result of azole pressure. Isolates contained either
G54R, G54V, P216L or M220R SNPs, all of which have previously been
proven to result in azole resistance to varying degrees (Bellete et al.,
2010; Bueid et al., 2010; Chen et al., 2005; Garcia-Eﬀron et al., 2005;
Hodiamont et al., 2009; Howard et al., 2009; Kuipers et al., 2011; Mann
et al., 2003; Mellado et al., 2003, 2007, 2004; Snelders et al., 2010;
Xiao et al., 2004). In most cases the Cyp51A SNP present did not fully
explain the resistance proﬁle observed, indicating the presence of ad-
ditional non-cyp51A mediated resistance mechanisms. As an example,
isolate V157-39 was highly resistant to both POS and ITR. This isolate
possessed a G54R substitution in Cyp51A, which has previously been
shown to confer ITR resistance (Mellado et al., 2003). The POS re-
sistance of this isolate is as yet unexplained.
Four isolates possessed SNP R188Q in Snf1 kinase; this protein is
known to be involved in nutrient limitation and salt stress responses in
Saccharomyces cerevisiae (Hsu et al., 2015; Sanz, 2003). It is possible
that R188Q alters Snf1 functionality, potentially enhancing the ability
of the isolates to cope with these stresses, which could enable persis-
tence of infection. Furthermore, 7 isolates possessed SNP D347Y in C6
ﬁnger domain protein (AFUA_2G08040). This protein possesses RNA
polymerase II transcription factor activity and is zinc ion binding
(Bateman et al., 2015). Interestingly, Hagiwara et al also reported a
mutation (Y958) in this C6 ﬁnger domain protein, predicted to have
developed throughout infection in an invasive pulmonary aspergillosis
patient (Hagiwara et al., 2014). This supports our hypothesis that the
identiﬁed proteins are involved in in-host adaptation.
Fitness losses in clinical azole resistant A. fumigatus isolates are
frequently reported (Hagiwara et al. 2014; Valsecchi et al. 2015).
Various methods of assessing ﬁtness are described in A. fumigatus
(Arendrup et al., 2010; Lackner et al., 2017; Valsecchi et al., 2015). In
this study we performed liquid and solid media growth assays. These
growth assays were selected to represent diﬀerent forms of in vivo
growth. Liquid assays were deemed a basic representation of growth in
human tissue, where conidiation does not occur. Solid media assays
were chosen to crudely represent growth with sporulation, which oc-
curs when the fungus is in contact with the air, as on the epithelial
lining of the airways. Isolate V157-62 was shown to harbour defects in
both conidiation and growth on solid media. This isolate contains a
M220R Cyp51A mutation. Previous in vivo competition studies, using
both immunocompetent and immunosuppressed mice, have shown that
M220 SNPs are not associated with ﬁtness costs (Lackner et al., 2017;
Valsecchi et al., 2015). It is possible that other SNPs gained as a result
of adaptation are the cause of this ﬁtness defect. These SNPs could be
either beneﬁcial and associated with a ﬁtness cost or simply dis-
advantageous. Clues can be obtained using whole genome sequencing
however further research is required to deﬁnitively associate speciﬁc
SNPs, or combinations thereof, with this phenotype.
Later isolates were shown to produce signiﬁcantly fewer conidia
than earlier more susceptible isolates. Conidiation in speciﬁc isolates
was restored in the presence of itraconazole. This could be classiﬁed as
Fig. 7. Survival of Galleria mellonella larvae infected with speciﬁc isolates. Groups of 10
G. mellonella larvae were infected with 6×103 conidia in the last pro-leg using a 0.33mm
Micro-Fine needle. Two control groups of larvae were included in each experiment; 10
unmanipulated larvae and 10 larvae injected with phosphate-buﬀered saline. Larvae were
monitored for 6 d; larval death was characterised by lack of movement and melanisation.
Survival after infection with isolate V157-62 or V135-39 was signiﬁcantly higher in
comparison to isolate V130-15 (*p < 0.05; two-tailed Students T-test).
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azole addiction, where the fungus has adapted to grow in the presence
of azole and as a result requires it for speciﬁc aspects of growth. These
isolates do not share an isolation date or resistance proﬁle, but perhaps
shared localisation within the lung and therefore adapted similarly. As
the majority of isolates possessed normal mycelial growth rates, the
defect lies directly in the isolates’ ability to form conidia. In agreement
with our ﬁndings, Hagiwara et al also reported a sporulation defect in
serially isolated clinical strains from individual patients (Hagiwara
et al., 2014). It can be hypothesised that the virulence of the poorly
sporulating isolates is unaﬀected by this defect as conidiation is rarely
observed in human tissue and is not required for invasive disease pa-
thogenesis. However, the environmental spread of resistant isolates
with this defect is likely to be limited.
Interestingly, under zinc depletion isolates grew better at pH 7.5 in
comparison to pH 4.5. ZrfC is central to this behaviour. This zinc
transporter is capable of functioning under alkaline zinc limiting con-
ditions due to its N-terminus, which is also predicted to scavenge Zn2+
from host tissues (Amich et al., 2014; Wilson et al., 2012). It is probable
that these strains have evolved in host and are therefore more adapted
to scavenge zinc and thrive at physiological pH in host. Survival in
acidic conditions is perhaps driven by adaptation to the ecological
niche of A. fumigatus in soil. The SNP identiﬁed by us in the ZrfC in
V157-80 did not inﬂuence the capability to grow in alkaline zinc lim-
iting conditions and seems not to play a role in in-host adaptation.
The phenotypic and genotypic changes observed in the series may
be associated with the virulence diﬀerences observed in our experi-
mental G. mellonella model. Isolates exhibited both increased and de-
creased virulence in comparison to the precursor isolate (V130-15). The
isolate determined to have a growth defect in vitro (V157-62) showed
attenuated virulence in comparison to V130-15. This could be a direct
impact of its slower mycelial growth. Another azole resistant isolate
(V157-39) showed enhanced virulence in comparison to V130-15. In
agreement with previous ﬁndings, no associations could be made be-
tween resistance development and changes in virulence (Lackner et al.,
2017; Valsecchi et al., 2015). Furthermore, no associations could be
made between conidiation levels and virulence. As mycelial growth
drives invasion in-host rather than conidiation, it is possible that dif-
ferences in conidiation ability have minimal impact on ability to cause
infection. It is likely that microevolution has driven both increases and
decreases in virulence. Attenuated virulence may well be a cost asso-
ciated with another yet unidentiﬁed adaptation mechanism. Increases
in virulence are regarded as direct adaptation to enable persistence.
5. Conclusions
In summary, A. fumigatus undergoes substantial in-host adaptation.
This adaptation occurs on both a physiological and genetic level as il-
lustrated by our results, and is hypothesised to enable persistence of
infection in some cases. Genetic changes reported here are wide ran-
ging, suggesting that the stressors driving adaptation are equally wide
ranging. It should be noted that as this study involves a series of isolates
from a single chronic granulomatous disease patient, adaptation dy-
namics reported may not be representative of other patient groups and/
or other patients with chronic granulomatous disease. However, this
study is the ﬁrst to provide in depth analysis into the genetic and
physiological changes that occur in A. fumigatus during adaptation to
the human host.
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Appendix A
Table A.1
Table A.2
Table A1
Mean coverage and mapping quality of whole genome sequence data sets to Af293 reference.
Strain Mean coverage (X) Mean mapping quality
V130-15 69 40
V130-14 85 39
V130-18 118 39
V130-54 69 39
V157-39 62 40
V157-40 76 41
V157-47 20 37
V157-48 25 37
V157-62 53 41
V157-59 77 40
V157-60 58 41
V157-61 61 39
V157-80 71 41
Mean across series 65 40
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